• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Abbott Laboratories (NY: ABT )

    113.34 -1.47 (-1.28%)
    Official Closing Price Updated: 4:10 PM EDT, Sep 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,029,907
    Open 114.21
    Bid (Size) 113.01 (1)
    Ask (Size) 113.93 (1)
    Prev. Close 114.81
    Today's Range 113.18 - 114.41
    52wk Range 89.67 - 121.64
    Shares Outstanding 1,750,942,289
    Dividend Yield 1.80%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
    Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech growth and attractive valuation. 
    Via Benzinga
    This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga

    Performance

    YTD
    +3.18%
    +3.18%
    1 Month
    +0.57%
    +0.57%
    3 Month
    +7.64%
    +7.64%
    6 Month
    +3.03%
    +3.03%
    1 Year
    +16.28%
    +16.28%

    More News

    Read More
    20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
    Via MarketBeat
    Topics Economy
    Exposures Economy Interest Rates
    Why ABBOTT LABORATORIES (NYSE:ABT) should be investigated by quality investors.
    Via Chartmill
    Looking Into Abbott Laboratories's Recent Short Interest
    Via Benzinga
    Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
    Via The Motley Fool
    Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
    Via The Motley Fool
    3 Stocks to Buy and Hold Forever
    Via The Motley Fool
    3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold
    Via The Motley Fool
    2 Stocks That Are Passive Income Machines to Buy and Hold Forever
    Via The Motley Fool
    Medtronic Stock: Growth On Rise of the Cardiovascular Machines
    Via MarketBeat
    Abbott Laboratories Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
    Via Benzinga
    Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System
    Via Benzinga
    Topics Product Recall
    Exposures Legal Product Safety
    Abbott's 'Transformative' Move And Answer To Dexcom's Newest Device
    Via Investor's Business Daily
    Patchy But Still Bullish
    Via Talk Markets
    3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
    Via The Motley Fool
    Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
    Via Benzinga
    Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
    Via Benzinga
    Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?
    Via Investor's Business Daily
    This Is Great News for Medtronic, but Is It Time to Buy the Stock?
    Via The Motley Fool
    Donald Trump Owns These 21 Dividend Kings. Should You?
    Via The Motley Fool
    Topics Government
    Exposures Political
    3 Unstoppable Dividend Stocks to Buy Right Now
    Via The Motley Fool
    Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally
    Via MarketBeat
    Exposures Product Safety
    Abbott Laboratories, Nu Holdings And More On CNBC's 'Final Trades'
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.